Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal

Molecular Pharmaceutics

Volumn 6, Issue 1, 2009, Pages 98-104

  Mitoxantrone, ^a   Kawano, Kumi ^a   Onose, Eri ^a   Hattori, Yoshiyuki ^a   Maitani, Yoshie ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Folate targeting; Liposome; Membrane fluidity; Mitoxantrone

Indexed keywords

AMINO POLY(ETHYLENEGLYCOL)DISTEARYLPHOSPHATIDYLETHANOLAMINE; DIMYRISTOYL PHOSPHATIDYLCHOLINE; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; FOLATE RECEPTOR; LIPOSOME; MITOXANTRONE; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FOLIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID MEMBRANE; MEMBRANE FLUIDITY; PRIORITY JOURNAL; SLOW DRUG RELEASE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; FOLIC ACID; HUMANS; LIPOSOMES; MITOXANTRONE;

EID: 62649142888     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800069c     Document Type: Article

References (24)

1. Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 1997, 74 (2), 193-198.
2. Weitman, S. D.; Lark, R. H.; Coney, L. R.; Fort, D. W.; Frasca, V.; Zurawski, V. R., Jr.; Kamen, B. A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992, 52 (12), 3396-3401.
3. Gabizon, A.; Horowitz, A. T.; Goren, D.; Tzemach, D.; Shmeeda, H.; Zalipsky, S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 2003, 9 (17), 6551-6559.
4. Pan, X. Q.; Wang, H.; Lee, R. J. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm. Res. 2003, 20 (3), 417-422.
5. Gabizon, A.; Horowitz, A. T.; Goren, D.; Tzemach, D.; Mandel- baum-Shavit, F.; Qazen, M. M.; Zalipsky, S. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)- grafted liposomes: in vitro studies. Bioconjugate Chem. 1999, 10 (2), 289-298.
6. Saul, J. M.; Annapragada, A.; Natarajan, J. V.; Bellamkonda, R. V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Controlled Release 2003, 92 (1-2), 49-67.
7. Kawano, K.; Maitani, Y. Effect of PEG spacer length and ligand density on folate receptor targeting of liposomal doxorubicin. Drug Dev. Ind. Pharm., submitted.
8. Turk, M. J.; Reddy, J. A.; Chmielewski, J. A.; Low, P. S. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim. Biophys. Acta 2002, 1559 (1), 56-68.
9. Lim, H. J.; Masin, D.; McIntosh, N. L.; Madden, T. D.; Bally, M. B. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J. Pharmacol. Exp. Ther. 2000, 292 (1), 337-345.
10. Lim, H. J.; Masin, D.; Madden, T. D.; Bally, M. B. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp. Ther. 1997, 281 (1), 566-573.
11. Wu, M.; Gunning, W.; Ratnam, M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 1999, 8 (9), 775-782.
12. Adlakha-Hutcheon, G.; Bally, M. B.; Shew, C. R.; Madden, T. D. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat. Biotechnol. 1999, 17 (8), 775-779.
13. Regev, R.; Yeheskely-Hayon, D.; Katzir, H.; Eytan, G. D. Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem. Pharmacol. 2005, 70 (1), 161-169.
14. Shiokawa, T.; Hattori, Y.; Kawano, K.; Ohguchi, Y.; Kawakami, H.; Toma, K.; Maitani, Y. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Clin. Cancer Res. 2005, 11 (5), 2018-2025.
15. Horowitz, A. T.; Barenholz, Y.; Gabizon, A. A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim. Biophys. Acta 1992, 1109 (2), 203-209.
16. Lee, R. J.; Low, P. S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1995, 1233 (2), 134-144.
17. Shmeeda, H.; Mak, L.; Tzemach, D.; Astrahan, P.; Tarshish, M.; Gabizon, A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol. Cancer Ther. 2006, 5 (4), 818-824.
18. Johnston, M. J.; Semple, S. C.; Klimuk, S. K.; Edwards, K.; Eisenhardt, M. L.; Leng, E. C.; Karlsson, G.; Yanko, D.; Cullis, P. R. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim. Biophys. Acta 2006, 1758 (1), 55-64.
19. Johnson, J. L.; Ahmad, A.; Khan, S.; Wang, Y. F.; Abu-Qare, A. W.; Ayoub, J. E.; Zhang, A.; Ahmad, I. Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation. J. Chromatogr. B 2004, 799, 149-155.
20. Maitani, Y.; Katayama, S.; Kawano, K.; Hayama, A.; Toma, K. Artificial Lipids Stabilized Camptothecin Incorporated into Liposomes. Biol. Pharm. Bull. 2008, 31 (5), 990-993.
21. Kawano, K.; Nakamura, K.; Hayashi, K.; Nagai, T.; Takayama, K.; Maitani, Y. Liver targeting liposomes containing beta-sitosterol glucoside with regard to penetration-enhancing effect on HepG2 cells. Biol. Pharm. Bull. 2002, 25 (6), 766-770.
22. Ugwu, S.; Zhang, A.; Parmar, M.; Miller, B.; Sardone, T.; Peikov, V.; Ahmad, I. Preparation, characterization, and stability of liposome-based formulations of mitoxantrone. Drug Dev. Ind. Pharm. 2005, 31 (2), 223-229.
23. Anderson, M.; Omri, A. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Delivery 2004, 11 (1), 33-39.
24. Kobayashi, T.; Ishida, T.; Okada, Y.; Ise, S.; Harashima, H.; Kiwada, H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 2007, 329 (1-2), 94-102.